Alexion Pharmaceuticals Inc.’s Soliris recently became the first product to gain a US and EU approval for the rare disease neuromyelitis optica spectrum disorder (NMOSD), but Roche and Viela Bio Inc. are hot on its heels with competitors.
Both challengers presented data at this week's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting taking place...